Navigation Links
Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
Date:12/10/2008

e combination of the endonuclease plus either purine analogue. The combination of doxorubicin with ONCONASE or R-Amph demonstrated an increase in pro-apoptotic activity when compared to single agent treatment, although the effect was not statistically significant. This is the first study showing cytotoxic, pro-apoptotic effects of ONCONASE and R-Amph in CLL, and synergism with the most widely used CLL therapies.

For the study in AML, leukemic cells isolated from 22 patients with newly diagnosed AML were cultured for 24-72 hours with either ONCONASE or R-Amph alone and in combination with doxorubicin or cytarabine arabinoside. In these experiments, both endoribonucleases showed significant activity against AML cells. The main mechanism of this action was shown to be the triggering of caspase-dependent apoptosis by activation of the mitochondrial pathway. The combination of ONCONASE or R-Amph with doxorubicin in AML exhibited significant synergistic cytotoxicity, and offers insights into the potential therapeutic enhancement for doxorubicin, from a class of drugs commonly used as first line therapy in AML.

"These ex vivo studies expand the potential of ONCONASE as a potential treatment for various leukemias," said Kuslima Shogen, Alfacell's chief executive officer. "Based on our knowledge of the impact of ONCONASE on cellular pathways involved in tumor cell growth, and also in resistance to chemotherapy, additional studies may further demonstrate ONCONASE's promising anti-leukemic activity."

About AML

AML (acute myeloblastic leukemia) is a cancer of the myeloid line of white blood cells, characterized by the rapid proliferation of abnormal cells which accumulate in the bone marrow and interfere with the production of normal blood cells. AML is a potentially curable disease; but only a minority of patients are cured with current therapy. AML is treated initially with chemo
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
2. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
6. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
7. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 News Facts ... devoted to genome-based research for human health and ... is taking a bite out of oral cancer with its ... India with the help of state-of-the-art ... Networks (DDN). , To fuel its cutting-edge cancer research, ...
(Date:9/23/2014)... , September 23, 2014 ... System Transfer     Devices  (CSTD) for ... with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading CSTD ... Taiwan , China ... company continues to expand globally, and throughout the ...
(Date:9/23/2014)... The Minnesota High Tech Association (MHTA) ... modems , platforms and application-specific remote monitoring systems, ... the 2014 Tekne Awards. The awards ceremony ... Center on Thursday, November 13th. The Tekne Awards ... superior technology innovation and leadership. , The ...
(Date:9/22/2014)... , September 22, 2014 ... announced the addition of the "Global Biotechnology ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology ... added to a system to detect and examine ... are generally used in laboratories to prepare, collect, ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3
... GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta-based biotechnology ... an,operational update for the quarter ended June 30, 2007. ... 2007 The Company recorded a net loss of ... to net income of $197,750 for the same period,in ...
... Transgenomic, Inc. (the,"Company") (OTC Bulletin Board: TBIO) today ... The Company,s financial results are,presented in the tables that ... a net profit of $0.2 million or $0.00 per ... a net loss of $0.4 million or,$0.01 per share ...
... Martek Biosciences,Corporation announced that it intends to release ... September 5, 2007, at approximately 4:00 p.m.,Eastern Daylight Time ... hold a conference call to discuss the results of ... is expected to be approximately one,hour in duration. The ...
Cached Biology Technology:GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 6Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Martek to Announce Third Quarter 2007 Results on September 5, 2007 2
(Date:9/23/2014)... proteins to survive in the icy Southern Ocean ... by the National Science Foundation (NSF) report: The ... resist melting even when temperatures warm. , ... consequence of the evolution of antifreeze proteins in ... student Paul Cziko, who led the research with ...
(Date:9/23/2014)... the body forms new tissues during the healing ... each other. For years, scientists believed this communication ... Carnegie Mellon University and the University of Pittsburgh ... is equally if not more crucial. The ... Proceedings of the National Academy of Sciences ...
(Date:9/23/2014)... have scoured cow rumens and termite guts for microbes ... the production of next-generation biofuels, but some of the ... lower intestine, researchers report. , Their study , ... of Sciences , is the first to use biochemical ... human gut can digest fiber, breaking it down into ...
Breaking Biology News(10 mins):Antifreeze proteins in Antarctic fish prevent both freezing and melting 2Antifreeze proteins in Antarctic fish prevent both freezing and melting 3The mechanics of tissue growth 2Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3
... Liver transplant patients with hepatitis C virus (HCV) ... the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination ... virus in vitro. , The results of ... of Liver Transplantation, the official journal of the ...
... infants born with HIV infection may be most effective ... according to a study published in the April 1 ... online. , Uncertainty over when to start antiretroviral treatment ... around balancing the benefits of preventing disease progression and ...
... in which single strands of synthetic DNA are used ... been developed by researchers with the Lawrence Berkeley National ... Berkeley. This technique holds promise for a wide ... of artificial tissues and the design of neural networks. ...
Cached Biology News:Cyclosporine inhibits hepatitis C virus in vitro 2New study shows benefit of early therapy in HIV-infected infants 2Berkeley researchers lay groundwork for cell version of DNA chip 2Berkeley researchers lay groundwork for cell version of DNA chip 3Berkeley researchers lay groundwork for cell version of DNA chip 4